In vitro and in vivo pharmacological profile of the selective β3-adrenoceptor agonist mirabegron in rats

被引：41

作者：

Hatanaka, Toshiki ^{[1
]}

Ukai, Masashi ^{[1
]}

Watanabe, Mai ^{[1
]}

Someya, Akiyoshi ^{[1
]}

Ohtake, Akiyoshi ^{[1
]}

Suzuki, Masanori ^{[1
]}

Ueshima, Koji ^{[1
]}

Sato, Shuichi ^{[1
]}

Sasamata, Masao ^{[1
]}

机构：

[1] Astellas Pharma Inc, Appl Pharmacol Res Labs, Drug Discovery Res, Tsukuba, Ibaraki 3058585, Japan

来源：

NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY | 2013年 / 386卷 / 03期

关键词：

Mirabegron; beta(3)-Adrenoceptor agonist; Overactive bladder; Cerebral infarcted rat; CEREBRAL-ARTERY OCCLUSION; OVERACTIVE BLADDER; DETRUSOR OVERACTIVITY; BETA-3-ADRENOCEPTOR; RELAXATION; EFFICACY; TOLERABILITY; MECHANISMS; SUBTYPES; YM178;

D O I：

10.1007/s00210-012-0821-4

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

To investigate the pharmacological properties of mirabegron in in vitro and in vivo, the effects on cAMP accumulation in Chinese hamster ovary (CHO) cells expressing rat beta-adrenoceptors, the relaxant activity in isolated rat bladder smooth muscle, and the voiding effects in cerebral infarcted rats were evaluated. Mirabegron increased cAMP accumulation with EC50 value and intrinsic activity of 19 nmol/L and 1.0, respectively, in CHO cells expressing rat beta(3)-adrenoceptors. The EC50 values and the intrinsic activities of mirabegron were 610 nmol/L and 0.6 for rat beta(1)-adrenoceptors and were sumless and 0.1 for beta(2)-adrenoceptors, respectively. Mirabegron showed concentration-dependent relaxant and full agonistic effects in rat bladder strips under passive tension with EC50 value of 290 nmol/L. The concentration-response curve of mirabegron was affected neither by the beta(1)-adrenoceptor selective antagonist CGP-20712A nor by the beta(2)-adrenoceptor selective antagonist ICI-118,551. In in vivo studies with cerebral infarcted rats, a significant decrease in the volume voided per micturition compared with sham-operated rats was observed. Mirabegron dose-dependently increased the volume voided per micturition. In conclusion, we have extended the selectivity profile of mirabegron to rats and demonstrated that it is effective via stimulation of beta(3)-adrenoceptors in a rat cerebral infarction model of detrusor overactivity.

引用

页码：247 / 253

页数：7

共 50 条

[21] Mirabegron, A Selective β 3 -Adrenoceptor Agonist Causes an Improvement in Erectile Dysfunction in Diabetic Rats [J].

Yilmaz-Oral, Didem ;

Kaya-Sezginer, Ecem ;

Askin, Dilan ;

Hamurtekin, Yesim ;

Gur, Serap .

EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES, 2021, 129 (04) :296-302

[22] Effects of Mirabegron, a Novel β3-Adrenoceptor Agonist, on Primary Bladder Afferent Activity and Bladder Microcontractions in Rats Compared With the Effects of Oxybutynin [J].

Aizawa, Naoki ;

Homma, Yukio ;

Igawa, Yasuhiko .

EUROPEAN UROLOGY, 2012, 62 (06) :1165-1173

[23] Pharmacological Effect of TRK-380, a Novel Selective Human β3-Adrenoceptor Agonist, on Mammalian Detrusor Strips [J].

Kanie, Sayoko ;

Otsuka, Atsushi ;

Yoshikawa, Satoru ;

Morimoto, Takashi ;

Hareyama, Nana ;

Okazaki, Seiji ;

Kobayashi, Ryosuke ;

Hasebe, Ko ;

Nakao, Kaoru ;

Hayashi, Ryoji ;

Mochizuki, Hidenori ;

Matsumoto, Rikiya ;

Ozono, Seiichiro .

UROLOGY, 2012, 79 (03) :744.e1-744.e7

[24] Identification of Uridine 5'-Diphosphate-Glucuronosyltransferases Responsible for the Glucuronidation of Mirabegron, a Potent and Selective β3-Adrenoceptor Agonist, in Human Liver Microsomes [J].

Konishi, Kentaro ;

Tenmizu, Daisuke ;

Takusagawa, Shin .

EUROPEAN JOURNAL OF DRUG METABOLISM AND PHARMACOKINETICS, 2018, 43 (03) :301-309

[25] Efficacy and safety of mirabegron, a β3-adrenoceptor agonist, for treating neurogenic bladder in pediatric patients with spina bifida: a retrospective pilot study [J].

Park, Jee Soo ;

Lee, Yong Seung ;

Lee, Cho Nyeong ;

Kim, Sung Hoon ;

Kim, Sang Woon ;

Han, Sang Won .

WORLD JOURNAL OF UROLOGY, 2019, 37 (08) :1665-1670

[26] Onset of action of the β3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder [J].

Christopher R. Chapple ;

Victor W. Nitti ;

Vik Khullar ;

Jean Jacques Wyndaele ;

Sender Herschorn ;

Philip van Kerrebroeck ;

Mary Beth Blauwet ;

Emad Siddiqui .

World Journal of Urology, 2014, 32 :1565-1572

[27] Absorption, Metabolism and Excretion of [14C]Mirabegron (YM178), a Potent and Selective β3-Adrenoceptor Agonist, after Oral Administration to Healthy Male Volunteers [J].

Takusagawa, Shin ;

van Lier, Jan Jaap ;

Suzuki, Katsuhiro ;

Nagata, Masanori ;

Meijer, John ;

Krauwinkel, Walter ;

Schaddelee, Marloes ;

Sekiguchi, Mitsuhiro ;

Miyashita, Aiji ;

Iwatsubo, Takafumi ;

van Gelderen, Marcel ;

Usui, Takashi .

DRUG METABOLISM AND DISPOSITION, 2012, 40 (04) :815-824

[28] Efficacy and Safety of the Selective β3-Adrenoceptor Agonist Mirabegron in Japanese Patients with Overactive Bladder: A Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study [J].

Yamaguchi, Osamu ;

Marui, Eiji ;

Igawa, Yasuhiko ;

Takeda, Masayuki ;

Nishizawa, Osamu ;

Ikeda, Yasushi ;

Ohkawa, Sumito .

LUTS-LOWER URINARY TRACT SYMPTOMS, 2015, 7 (02) :84-92

[29] β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men [J].

Otsuki, Hideo ;

Kosaka, Takeo ;

Nakamura, Kenzo ;

Mishima, Junnji ;

Kuwahara, Yoshitaka ;

Tsukamoto, Takuji .

INTERNATIONAL UROLOGY AND NEPHROLOGY, 2013, 45 (01) :53-60

[30] β3-Adrenoceptor agonist mirabegron is effective for overactive bladder that is unresponsive to antimuscarinic treatment or is related to benign prostatic hyperplasia in men [J].

Hideo Otsuki ;

Takeo Kosaka ;

Kenzo Nakamura ;

Junnji Mishima ;

Yoshitaka Kuwahara ;

Takuji Tsukamoto .

International Urology and Nephrology, 2013, 45 :53-60

← 1 2 3 4 5 →